Latest News and Press Releases
Want to stay updated on the latest news?
-
InterDigital's Atle Monrad re-elected to Chair 3GPP SA6, responsible for service architecture, procedures, and information flows that enable applications.
-
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming...
-
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli...
-
Austin, TX, USA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Digital Experience Platform DXP Market Size, Trends and Insights By Component...
-
Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Frost Radar: Workforce Engagement Management, 2025" report has been added to ResearchAndMarkets.com's offering.A Benchmarking System to Spark...
-
Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The "Understanding and Managing Contracts to Achieve Better Results Training Course (April 15-16, 2026)" training has been added to ...
-
Zipline Surpasses 2 Million Deliveries, Raises More than $600M, and Expands Operations to Houston and Phoenix
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Building and Managing a Patent Portfolio to Best Support your Business Training Course (May 11, 2026)" has been added to ResearchAndMarkets.com's...